The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent
DUBLIN , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system1 designed to improve deliverability and increase acute performance2 in even the most challenging of cases.1
The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD), which is caused by plaque buildup on the inside of the coronary arteries. These plaque deposits can narrow or clog the inside of the arteries, which decreases the supply of blood and oxygen to the heart. CAD is the leading cause of death for both men and women in the United States .3 To help to restore blood flow, a physician may use a stent (a flexible metal scaffolding) that is delivered during a minimally invasive procedure to prop open the artery. A drug-eluting stent is the most common type of stent used to treat a blockage of the heart arteries.4
"The new Onyx Frontier DES, with its enhanced deliverability, will continue to help interventional cardiologists treat complex coronary cases and larger ranges of vessel sizes more efficiently," said Azeem Latib , M.D., section head of interventional cardiology and medical director of structural heart interventions at Montefiore Medical Center in New York City . "Delivering safe and effective outcomes to our patients is our number one priority. It's important that physicians have access to tools like the Onyx Frontier DES that can allow them to efficiently achieve those outcomes."
Meaningful design changes, including increased catheter flexibility, an innovative dual-layer balloon technology and a lower crossing profile led to a 16% improvement in deliverability with Onyx Frontier vs. the previous generation Resolute Onyx DES.2 In addition to the delivery system enhancements, Onyx Frontier offers a broad size matrix to treat more patients and is the only 2.0 mm DES available in the United States (similar to Resolute Onyx). Further, Onyx Frontier continues to provide 4.50-5.00 mm sizes that can be expanded to 6.00 mm - specifically designed to support extra-large vessels. Onyx Frontier shares the same clinical indications as Resolute Onyx, including the most recent approval for patients that are at high risk of bleeding who may benefit from a dual antiplatelet therapy (DAPT) duration as short as one month.2
"The Onyx Frontier DES FDA approval is a very important milestone for Medtronic's Coronary business and demonstrates our commitment to interventional cardiologists by providing best-in-class products," said Jason Weidman , senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. "The Onyx Frontier launch also correlates directly to Medtronic's commitment to engineering. The team built upon the design and clinical successes of the Resolute Onyx DES and has continued to evolve proven DES technology to further address the needs of physicians. We look forward to continuing the pursuit of innovation each day."
The Onyx Frontier DES is now approved in the United States and is pending CE (Conformité Européene) Mark.
About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1 Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx Frontier DES diameters. 2 Bench test data on file at Medtronic. May not be indicative of clinical results. 3 National Heart, Lung and Blood Institute 4 Mayo Clinic Staff. Drug-Eluting Stents: Do they increase heart attack risk? Mayoclinic.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-approval-for-latest-generation-drug-eluting-coronary-stent-system-301546666.html
Sens. Patty Murray (D-Wash.) and Bob Casey (D-Pa.) have led the congressional response to the formula crisis.
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
The U.S. Food and Drug Administration approved Eli Lilly novel treatment for diabetes on Friday, in a widely anticipated move after the drug led to impressive drops in blood sugar and body weight in clinical trials. Lilly stock (ticker: LLY) closed up just 0.3% Friday, at $291.63, but it has proved a favorite even in a faltering market. While the has dropped 4.4% in the past 12 months, Lilly shares are up 50%.
"I was in a medically induced coma for six weeks. There were times I was fully conscious, but I couldn't open my eyes, couldn't move a muscle, and couldn't speak. It was terrifying."View Entire Post ›
The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.
Bill Gates said Friday on CNN that it is “tragic” if conspiracy theories about him are keeping people from getting vaccinated against COVID-19. Addressing theories surrounding his involvement in vaccine production, Gates said, “The one about tracking people, I don’t know why they think I’m interested in knowing people’s locations — that one I still…
The Army is weighing new policies in response to the Supreme Court's expected decision to reverse Roe v. Wade and eliminate protections on abortion rights across the country, the service's senior enlisted leader told Congress.
“There's plenty of blame to go around here,” says one expert.
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Despite the popularity of vegan and vegetarian diets, a majority of people in the U.S. still do eat meat. In fact, according to a 2021 survey from Ipsos, 9 in 10 Americans currently include meat as part of their diet. With that in mind, it won't be hard for most to spot the symptoms of a concerning health condition that's becoming more and more of a problem thanks to another rising trend. Researchers are warning that the increasing prevalence of one pest across the country could have serious con
More than two years into the pandemic, there is plenty to celebrate but just as many ongoing concerns. In the last week alone, infections have increased by more than 21 percent and hospitalizations have gone up by over 16 percent, according to the Centers for Disease Control and Prevention (CDC). Just a month ago, the numbers were consistently and substantially dropping—and the about-face since then has been a stark reminder that the path forward is likely to be less linear than many of us had h
Fiber has a lot to offer—it can support your gut health, help you lose weight or and even keep you feeling full for longer. To help you reap the benefits of getting enough fiber each day, these breakfasts include at least 6 grams of fiber per serving. Plus, each recipe focuses on complex carbs, like whole grains, and sticks to heart-healthy levels of saturated fat and sodium for a meal that fits perfectly into a diabetes-friendly routine.
(Reuters) -The U.S. Food & Drug Administration said on Friday it had approved Eli Lilly's injected drug tirzepatide, which has the brand name Mounjaro, to help improve blood sugar control in adults with type 2 diabetes. The FDA said Mounjaro, along with diet and exercise, improved blood sugar levels and was more effective than the other diabetes therapies with which it was compared in clinical studies. Mounjaro is designed to activate receptors for hormones involved in blood sugar control.
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
Katy Perry's legs are looking seriously toned as she dons a corset dress and heels on 'American Idol.' The singer doesn't love the gym but enjoys hiking.
Top health officials warn COVID-19 projection models show a significant wave is on the horizon. They're urging people to get vaccinated and boosted. https://www.abcactionnews.com/news/coronavirus/health-officials-urge-covid-19-vaccinations-and-boosters-as-cases-rise
Lung cancer patients could survive twice as long after a “pioneering” drug was approved on the NHS.
SEOUL, South Korea — South Korea has a reputation for world-class medical care. But faith in its hospitals has been shaken by years of complaints about doctors mishandling unconscious patients, including turning them over to unsupervised assistants who perform what are known as “ghost surgeries.” To stem the practice, lawmakers amended the country’s medical laws last year to require cameras in all operating rooms that handle patients under general anesthesia, making South Korea one of the first
Dr. Anthony Fauci, the nation’s top infectious disease specialist, told The Root today that cases of the deadly Covid-19 virus are slowly rising again across the country and warned that Black Americans could be particularly at risk in the event a more aggressive variant should appear. Fauci spoke with The Root this afternoon where he clarified his own comments about where the nation stood on the status of the pandemic as the country nears the milestone of 1 million deaths from the virus, which o
A baby-formula shortage that has been slowly intensifying for months is now reaching a state of emergency in the US: over 40 percent of formula is out of stock across the country, according to a report from Datasembly. Caregivers faced with empty shelves are sharing stories of finding price-gouged bottles online and feeding their infants cows' milk or homemade or watered-down formula.